REGENXBIO Inc. SEC filings RGNX
REGENXBIO Inc. has 805 filings in SEC EDGAR's recent list, going back to Nov 7, 2013. Its latest annual report, Form ARS, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SC TO-I/A | Filing | Jul 6, 2026 | — |
| SC TO-I/A | Filing | Jul 1, 2026 | — |
| SC TO-I | Filing | Jun 3, 2026 | — |
| EFFECT | Filing | Dec 12, 2025 | — |
| CORRESP | Letter to the SEC | Dec 9, 2025 | — |
| EFFECT | Filing | Jun 25, 2025 | — |
| CORRESP | Letter to the SEC | Jun 23, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2025 | — |
| EFFECT | Filing | Apr 14, 2025 | — |
| POSASR | Filing | Mar 13, 2025 | — |
| SEC STAFF LETTER | Filing | Mar 29, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 1, 2021 | — |
| SEC STAFF LETTER | Filing | Sep 30, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 23, 2019 | — |
| CT ORDER | Filing | Apr 3, 2019 | — |
| RW | Filing | Aug 9, 2018 | — |
| CT ORDER | Filing | May 16, 2018 | — |
| 425 | 8-k | Oct 3, 2017 | — |
| 425 | Filing | Oct 2, 2017 | — |
| 425 | Filing | Sep 1, 2017 | — |
| 425 | 8-k | Aug 25, 2017 | — |
| CT ORDER | Filing | Mar 23, 2017 | — |
| EFFECT | Filing | Jan 6, 2017 | — |
| CORRESP | Letter to the SEC | Jan 4, 2017 | — |
| CT ORDER | Filing | Dec 27, 2016 | — |
| CT ORDER | Filing | Sep 17, 2015 | — |
| EFFECT | Filing | Sep 16, 2015 | — |
| CERTNAS | Auto-generated paper document | Sep 16, 2015 | — |
| CORRESP | Letter to the SEC | Sep 14, 2015 | — |
| CORRESP | Letter to the SEC | Sep 14, 2015 | — |
| 8-A12B | Filing | Sep 9, 2015 | — |
| CORRESP | Letter to the SEC | Aug 28, 2015 | — |
| CORRESP | Letter to the SEC | Aug 27, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2015 | — |
| DRSLTR | Filing | Aug 10, 2015 | — |
| DRS/A | Filing | Aug 10, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 28, 2015 | — |
| DRS | Filing | Jul 1, 2015 | — |
| D | Filing | May 28, 2015 | — |
| D | Filing | Jan 23, 2015 | — |
| D | Filing | Nov 7, 2013 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RGNX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1590877
- Former names
- ReGenX Biosciences, LLC (until Nov 7, 2013)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.